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Abstract
Purpose: A retrospective study to evaluate the effect of hyperbaric oxygen (HBO2) therapy on sternal infection
and osteomyelitis following median sternotomy.
Materials and methods: A retrospective analysis of patients who received sternotomy and cardiothoracic surgery
which developed sternal infection and osteomyelitis between 2002 and 2009. Twelve patients who received
debridement and antibiotic treatment were selected, and six of them received additional HBO2 therapy.
Demographic, clinical characteristics and outcome were compared between patients with and without HBO2
therapy.
Results: HBO2 therapy did not cause any treatment-related complication in patients receiving this additional
treatment. Comparisons of the data between two study groups revealed that the length of stay in ICU (8.7 ± 2.7
days vs. 48.8 ± 10.5 days, p < 0.05), duration of invasive (4 ± 1.5 days vs. 34.8 ± 8.3 days, p < 0.05) and non-
invasive (4 ± 1.9 days vs. 22.3 ± 6.2 days, p < 0.05) positive pressure ventilation were all significantly lower in
patients with additional HBO2 therapy, as compared to patients without HBO2 therapy. Hospital mortality was also
significantly lower in patients who received HBO2 therapy (0 case vs. 3 cases, p < 0.05), as compared to patients
without the HBO2 therapy.
Conclusions: In addition to primary treatment with debridement and antibiotic use, HBO2 therapy may be used as
an adjunctive and safe treatment to improve clinical outcomes in patients with sternal infection and osteomyelitis
after sternotomy and cardiothoracic surgery.
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Introduction
Patients with sternal infection and osteomyelitis after ster-
notomy and cardiothoracic surgery are uncommon, but
these serious complications could increase postoperative
mortality, morbidity and medical cost [1,2]. Ischemia and
hypoxia are postulated as the mechanism resulting in
development of sternal infection and osteomyelitis [3,4];
however, the current primary treatment only focuses on
early debridement and antibiotic use [5].
Hypobaric oxygen (HBO2) therapy, the administration
of 100% oxygen at 2 to 3 absolute atmosphere pressure
(ATA), has been widely used in the treatment of various
problem wounds and for refractory osteomyelitis [6,7].
Mechanisms of HBO2 therapy include reversing hypoxia,
reducing local edema, improving host immunity, enhan-
cing antibiotic activity [8,9]. There are only few reports
about the additional HBO2 therapy for patients who
develop sternal osteomyelitis after sternotomy. Most of
the results are effective and successful [10,11]. The aim of
this retrospective study was to evaluate the efficacy of
HBO2 therapy in patients with sternal infection and osteo-
myelitis after sternotomy and cardiothoracic surgery.
Methods and materials
During January 1
st, 2002 to December 31
th 2009, twelve
patients who developed sternal infection and osteomyelitis
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any medium, provided the original work is properly cited.following sternotomy and cardiothoracic surgery at Taipei
Veterans General Hospital were recruited. The study
was approved by the Institutional Review Board of the
Taipei Veterans General Hospital (approval number,
201009015IC). All study data were collected retrospec-
tively, so informed consent was not required.
The diagnosis of organ/space sternal surgical site infec-
tion(SSI) was according to the Center for Disease Control
(CDC) criteria: (1) the sternal SSI occurs after sternotomy
and cardiothoracic surgery; (2) the infection appears to be
related to the operation and could involve any part of the
anatomy other than the incision which was opened or
manipulated during the operation (organs or spaces).
Furthermore, at least one of the following criteria is
required: (1) purulent drainage from the organ/space of
sternal surgical site; (2) organism isolated from an asepti-
cally obtained culture of fluid or tissue in the organ/space
of sternal surgical site; (3) an abscess or other evidence of
infection involving the organ/space of sternal surgical site
found on direct examination; (4) diagnosis of organ/space
SSI by a surgeon or attending physician [12]. In addition,
sternal osteomyelitis was documented by computer tomo-
graphy of chest, surgical debridement pathology or osteo-
myelitis scans.
All patients were treated with empiric antibiotics initially
and then guided by culture report and antibiotic suscept-
ibility tests. Early debridement, daily antiseptic irrigation
a n dd r e s s i n gc h a n g ew e r ep e r f o r m e d .A f t e rt h ei n f e c t i o n
was under control, reconstruction of the wound with pec-
toralis or rectus muscle and omental flap rotation was per-
formed at the decision of the clinical physician. HBO2
therapy was performed in a multiplace chamber (HTK
1500/BS, Drägen, Siemens, Germany). Each session was
120 minutes long including three phases: compression,
oxygen breath and decompression. Compression and
decompression were performed with room air at a rate of
0.1 ATA per minute. At oxygen breath phase, all patients
breathed 100% oxygen under 2.5 ATA for 90 minutes
through a face mask that was fit well and secured with
head straps. During the treatment period, patients were
observed closely for acute illness or any complications.
HBO2 therapy sessions were daily from Monday to Friday
with a break of 2 days. The total number of sessions of
HBO2 therapy performed based on clinical outcome and
at the discretion of the clinical physician.
Statistical analysis
Statistical analysis was done using SPSS version 18.0
(SPSS Inc., Chicago IL). Continuous variables were
expressed as the mean ± standard deviation (SD). Con-
tinuous variables were compared with Wilcoxon’sr a n k
sume test and categorical variables were compared by
Fishers exact test. p < 0.05 was considered statistically
significant.
Results
During the study period, 12 patients (mean age 59 ±
4.5 years) fulfilling the entry criteria were selected. Among
these patients, 7 patients received coronary arterial bypass
surgery, 3 patients received thymectomy, 1 patient
received mitral valve replacement and 1 patient received
type A aortic dissection repair. They received computer
tomography of chest (n = 8), pathologic surgical debride-
ment (n = 3) or osteomyelitis scans (n = 7) for the diagno-
sis of sternal osteomyelitis. All patients received primary
treatments with debridement and empiric antibiotics treat-
ment, and then guided by antibiotic susceptibility tests. Six
of them received additional HBO2 therapy. The others did
not received HBO2 therapy because of the insurance or
risk of HBO2 therapy. The characteristics of the study
population are presented in Table 1 and there was no sig-
nificant difference between these two groups. The bacter-
iology data from sternal wound/pus, pleural effusion and
blood are listed in Table 2. Staphylococcus species were the
most common pathogens of sternal wound infection
(11/12, 91.7%) and bacteremia (5/6, 83.3%). Mixed infec-
tion due to Gram-positive and Gram-negative pathogens
was also identified in 2 patients (2/12, 16.7%). Mycobacter-
ium tuberculosis was found in one sternal pus/wound
pathogen. HBO2 therapy did not cause any treatment-
related complication in the study patients who received
this additional treatment. Besides, patients breathed with
room air when initiation ofH B O 2t h e r a p ya n dd i dn o t
receive mechanical ventilation, sedative or inotropic medi-
cation during HBO2 therapy. Total and average debride-
ment duration, debridement frequency, hospital admission
frequency and length of hospital stay were not significantly
Table 1 Characteristiscs of patients in HBO2 and control
group
HBO2(n = 6) Control(n = 6) p
Age, years 54.7 ± 7.4 63.3 + 5.5 0.267
Female 1(%17) 2(%34) 0.500
Smoke 3(%50) 3(%50) 0.716
Body mass index (kg/m
2) 24.7+1.5 24.7+1.5 0.749
Coronary artery disease 3(%50) 3(%83) 0.273
Hypertension 3(%50) 3(%50) 0.716
Atrial fibrillation 1(%17) 1(%17) 0.773
Myocardial infarction history 1(%17) 4(%67) 0.121
Hyperlipidemia 1(%17) 2(%34) 0.500
Congestive heart failure 0 2(%34) 0.227
COPD 1(%17) 1(%17) 0.773
Myasthenia gravis 2(%34) 0 0.227
Diabetes mellitus 1(%17) 3(%50) 0.333
Chronic renal insufficiency 0 1(%17) 0.600
Uremia 1(%17) 1(%17) 0.773
Body mass index: the weight in kilograms divided by the square of the height
in meters COPD: chronic obstructive pulmonary disease
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importantly, length of ICU stay (8.7 ± 2.7 days vs. 48.8 ±
10.5 days, p < 0.05), duration of invasive mechanical venti-
lation (MV) (4 ± 1.5 days vs. 34.8 ± 8.3 days, p < 0.05) and
duration of noninvasive positive pressure ventilation (NIV)
(4 ± 1.9 days vs. 22.3 ± 6.2 days, p < 0.05) were signifi-
cantly reduced in HBO2 therapy group (Table 3). In addi-
tion, hospital death (0 person vs. 3 persons, p < 0.05) w as
significantly lower in HBO2 therapy group (Table 4). The
causes of death in the control group were ischemic bowel
disease (n = 1), acute pancreatitis (n = 1) and mediastinitis
(n = 1).
Discussion
The incidence of sternal infection and osteomyelitis in
patients undergoing sternotomy for cardiothoracic surgery
is not common- stated as being less than 4% in several
reports; however, it is a serious complication that increases
the length of hospital stay, short-term and long term mor-
tality, and medical cost [4,13]. In the current study, we
demonstrated that in patients with sternal infection and
osteomyelitis after sternotomy and cardiothoracic surgery,
HBO2 therapy could be an adjunctive treatment to
improve clinical outcomes including the length of ICU
stay, duration of MV and NIV support, complications dur-
ing hospital stay, and hospital mortality.
Risk factors for deep sternal wound infection and
osteomyelitis after median sternotomy have been
reported that included: (1) preoperative factors: male,
chronic obstructive pulmonary disease, diabetes, New
York Heart Association congestive heart failure class,
reoperation and obesity; (2) intraoperative factors: cor-
onary artery bypass grafting, prolonged cardiopulmonary
bypass time and duration of surgery; (3) postoperative
factors: excessive postoperative bleeding, postoperative
inotropic support and prolonged time (>48 hours) on
mechanical ventilation [14-18]. In our study, although
patients in the control group compared to HBO2 group
had more above-mentioned risk factors, these differences
did not reach statistical significance. However, the poten-
tial influence by these risk factors might still play a role
on the patient outcome. Importantly, patients with the
co-morbidity of congestive heart failure have been men-
tioned the risk for acute pulmonary edema after HBO2
therapy [19]. Therefore, HBO2 therapy should be cau-
tious when be applied to these patients.
The pathophysiology of sternal wound infection and
osteomyelitis is hypoxia and ischemia [3,4]; therefore, the
administration of HBO2 therapy has theoretical benefit for
these patients. However, there are only few case reports
and non-randomized studies about the use of HBO2 ther-
apy in this patient population. Recently, Higuchi et al. pre-
sented 4 patients with sternal osteomyelitis after lung
transplantation who received surgical debridement, anti-
microbial treatment and adjunctive HBO2 therapy [10].
Three of them improved significantly and the authors con-
cluded that HBO2 therapy was safe and effective for the
management of infection complication. Barili et al also
conducted a prospective nonrandomized study to investi-
gate the effect of HBO2 therapy on organ/space sternal
surgical site infection (SSI) following cardiothoracic sur-
gery [20]. A total of 34 patients who developed organ/
space sternal SSI after cardiac surgery were enrolled and
divided into two groups according to whether HBO2 ther-
apy was offered or not. The relapsing, infection rate, the
duration of intravenous antibiotic use and total hospital
stay were significantly lower in patients with HBO2 ther-
apy than those without HBO2 therapy. In our study, we
further identified that HBO2 therapy alleviated the burden
of critical care by shortening the length of ICU stay, and
duration of MV and NIV support. Furthermore, it also
reduced complications during hospital stay and mortality
in patients with sternal infection and osteomyelitis after
sternotomy and cardiothoracic surgery. Although the total
length of hospital stay and total debridement frequency
were not significantly different between the HBO2 therapy
and control group, patients in HBO2 group tended to
receive more debridement frequencies and have more hos-
pital admissions that might contribute to longer length
hospital stay and better outcome.
The current treatment for sternal infection and osteo-
myelitis includes early recognition, early debridement,
collection of specimens for bacteria pathogen, use of
broad-spectrum antibiotics and a change in antibiotics
Table 2 Causative organisms of patients in HBO2 and
control group
HBO2 Control
Sternal pus/
wound
Methicillin sensitive Staphylococcus
aureus
01
Methicillin resistent Staphylococcus
aureus
5* 4
Coagulase negative Staphylococcus
species
01 *
Acinectobacter baumannii 01 *
Klebsiella pneumoniae 1* 0
Escherichia coli 1* 0
Mycobacterium tuberculosis 10
Pleural effusion Methicillin resistent Staphylococcus
aureus
12
Blood Methicillin resistent Staphylococcus
aureus
23
Acinectobacter baumannii 01 *
Serratia marcescens 01 *
Proteus mirabilis 01 *
Fungus 0 1*
* mixed infection
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the patient’s infection is under control, reconstruction of
the wound should be instituted, including rewiring, and
pectoralis or rectus muscle and omental flap rotation
[21-23]. HBO2 therapy might offer additional biochem-
ical and cellular effects. With the administration of
HBO2 therapy, the partial oxygen pressure in the wound
increases and promotes collagen matrix formation, angio-
genesis, osteoclast/osteoblast activity and bone union
[24-26]. Increased oxygen tension improves neutrophil
ability to kill bacteria. Some antibiotics such as aminogly-
cosides, fluoroquinolones, vancomycin and sulfonamides
have a synergistic effect when combined with HBO2 for
the treatment of bacterial infection [9]. HBO2 itself also
acts as an antibiotic agent against a broad spectrum of
Gram-positive and Gram-negative bacteria [9]. These
above-mentioned effects of HBO2 therapy might explain
how adjunctive HBO2 therapy provides additional bene-
fits to patients with sternal infection and osteomyelitis
and improves the clinical outcomes of such patients.
The timing of HBO2 therapy for SSI and sternal osteo-
myelitis after sternotomy has been discussed. Higuchi et
al. reported the initiation of HBO2 therapy for patients
with persistent osteomyelitis after standard treatment [10].
Barili et al started early HBO2 therapy after the diagnosis
of sternal surgical site infection [20]. Both studies demon-
strated the adjunctive benefit of HBO2 therapy. In our
study, the decision of HBO2 therapy was based on clinical
physicians, range from 2 weeks to months after the diag-
nosis of sternal osteomyelitis. However, the timing of
HBO2 therapy for sternal osteomyelitis to gain maximum
benefit requires further investigation.
Although the microbiologic pathogens from the sternal
pus/wound, pleural effusion and blood are diverse,
Gram-positive cocci remain the most common pathogens
in our retrospective study which is consistent with other
studies [27,28]. Interesting, mycobacterium tuberculosis
was found in one sternal pus/wound pathogen. Reactiva-
tion of pulmonary or mediastinal lymph node tuberculo-
sis, contamination of the operation field, and exogenous
exposure persons with active pulmonary tuberculosis
may hypothesize tuberculosis infection after cardiothor-
acic surgery [29,30]. The patient with sternal wound
infection of mycobacterium tuberculosis received surgical
debridement, combination antituberculous agent treat-
ment and HBO2 therapy and was finally discharged. It is
important to note that some of the patients with sternal
infection and osteomyelitis developed bacteremia (2/6 in
HBO2 therapy group, 4/6 in control group) which might
worsen the prognosis of patients. Based on our observa-
tions of this study, HBO2 therapy might improve sternal
infection and reduce the occurrence of bacteremia.
Limitations
Our study had several limitations that are worth noting.
This study was retrospective in nature; therefore certain
data might have been missing or poorly documented.
Second, the number of patients in this study was small.
Third, we only focused on the clinical outcomes of the
study patients; therefore, the local effects of HBO2 ther-
apy, such as tissue oxygenation, angiogenesis, and osteo-
clast/osteoblast activity were not observed.
Conclusion
HBO2 counteracts tissue hypoxia by elevating tissue
oxygen partial pressure, promotes wound healing, has
the synergistic effect when combined with some antibio-
tics and prevents infection. In this study, all patients
Table 3 Operative and postoperative details in HBO2 and control group
HBO2 Control p
Total debridement operation time (minutes) 437 ± 81.4 355 ± 82.9 0.873
Average debridement operation time (minutes) 94 ± 21.6 98.6 ± 16 0.522
Total debridement frequency 5.5 ± 1.5 3.8 ± 1.0 0.326
APACHE II score 19.7 ± 7.7 18.7 ± 3.7 0.749
Duration in ICU (days) 8.7 ± 2.7 48.8 ± 10.5 0.004
Duration with MV use (days) 4 ± 1.5 34.8 ± 8.3 0.008
Duration with NIV use (days) 4 ± 1.9 22.3 ± 6.2 0.015
HBO2 frequency 21.3 ± 2.5 0 <0.001
Hospital admission frequency 2.8 ± 0.4 2 ± 0.2 0.127
Total hospital length of stay (days) 151 ± 21 138 ± 37 0.757
MV: invasive mechanical ventilation
NI: non-invasive mechanical ventilation
Table 4 Outcome of patients in HBO2 and control group
HBO2 Control p
Death 0 3 0.046
Complications 0.9 ± 2.3 0.7 ± 5 0.059
Complication: seizure/stroke, acute myocardial infarction/arrhythmia,
bacteremia, pneumonia/empyema, acute pancreatitis, ischemic bowel disease,
upper gastrointestinal tract bleeding, hyperglycemia, acute renal failure
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for post-cardiothoracic surgery related sternal infection
and osteomyelitis achieved a favorable result. We sug-
gest a combination of aggressive surgical debridement,
antibiotic treatment and adjunctive HBO2 therapy for
patients who develop sternal infection and osteomyelitis
after cardiothoracic surgery.
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